Biosafe and Stemlife Sign a Long Term Supply Agreement

          Biosafe and StemLife Bhd. are pleased to announce that they have signed a long-term Supply Agreement in respect of StemLife's cord blood banking activities in Malaysia.

          Effective immediately, Biosafe is supplying its fully automated Sepax(R) cell processor and associated single use kits to StemLife, which will use Biosafe technology for all its cord blood processing requirements.

          Today most Netcord-affiliated public cord blood banks use Biosafe technology for processing, as do quality-conscious private cord blood banks around the world.

          Olivier Waridel, CEO of the Biosafe Group commented: "We are delighted to be entering into a long term agreement with such a prestigious company as StemLife. This is an important win for us as we are replacing a competitor's cell processing system, further increasing our footprint in Asia."

          Sophian Bin Abdul Rahman, CEO of StemLife Bhd commented: "We are very pleased to find in Biosafe Group, a partner who shares our core values of Care, Competence, Commitment and Credibility. State-of-the-art technology notwithstanding, Biosafe's strong local support ensures that StemLife will continue to provide peace of mind to all our clients that their cord blood units will always be processed in a timely and reliable manner."

          About the Biosafe Group

          Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and Sao Paulo) and is present in more than 50 countries, either directly or through distributors.

          About StemLife Bhd.

          StemLife was founded in 2001 and was the first cord blood bank in Malaysia. It was also the first and only listed cord blood bank on the Malaysian Stock Exchange since 2006. Collectively, more than 60,000 families have entrusted their baby's cord stem cells with StemLife in its Malaysia and Thailand facilities. In 2014, Cordlife Group Limited took a 31% stake in StemLife Malaysia making StemLife part of the largest cord blood banking group in South East Asia region with more than 120,000 cord blood units stored. To-date, StemLife has successfully released 15 cord blood units for transplantation.